Mary Beth Pelletier, PhD

Apogee Therapeutics
VP, Quality Control
Dr. Mary Beth Pelletier is currently the Head of Quality Control for Apogee Therapeutics, where the team develops novel antibodies engineered against validated targets as best-in-class therapies for immunological and inflammatory diseases. She has represented the Biotechnology Innovation Organization (BIO) on the ICH Expert Working Group (EWG) for Q2(R2) and Q14 since 2018, driving development of harmonized global guidance on analytical procedure development and validation. Prior to Apogee, Mary Beth was Head of Quality Control at Intellia, Head of Quality for Biogen's Gene Therapy Manufacturing greenfield startup in Research Triangle Park, NC, and she previously led Biogen QC Analytical Technology where her team supported development, optimization, validation, transfer, troubleshooting, and lifecycle maintenance of analytical methods for Biogen’s biologics and gene therapy portfolio from Phase 1 throughout the commercial lifecycle. Prior to that, Mary Beth worked in biologics formulation development and analytical development. Mary Beth earned a bachelor’s degree in chemistry from Northwestern University in Evanston, IL, a Ph.D. in chemistry from The Scripps Research Institute in La Jolla, CA, and an MBA from NC State University.